相关实验视频

Updated: May 21, 2025

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

监测阿尔茨海默氏病中Aβ沉积之前的酸化情况

Guannan Zhu^1,2, Hong Zhang^1,2, Ruoxi Xie^1,2

¹Department of Radiology and Huaxi MR Research Center (HMRRC), Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.

Advanced healthcare materials

|March 19, 2025

概括

在阿尔茨海默氏病模型中,早期的大脑酸性化先于粉样蛋白β沉积. 这种与乳酸运输中断相关的酸化,出现在斑块形成和认知衰退之前.

科学领域:

神经科学是一个神经科学.
生物化学生物化学
分子生物学分子生物学

背景情况:

阿尔茨海默病 (AD) 的特点是粉样β (Aβ) 斑块.
已知酸化促进了Aβ的聚合,这表明它在阿尔茨海默病的进展中发挥了作用.

研究的目的:

为了研究大脑酸化和Aβ沉积之间的时间关系.
探索推动AD早期酸化的潜在机制.

主要方法:

使用了一种新型的响应酸的近红外 (NIR) 光探测器.
采用了分子生物学技术,并监测了2至11个月的APP/PS1和野生型 (WT) 老鼠.

主要成果:

在3个月的APP/PS1小鼠中检测到显著的光 (酸化),在5个月的Aβ沉积之前.
酸化在5个月达到峰值,与Aβ沉积的开始相吻合,随后在8个月时出现认知缺陷.
在3个月大的APP/PS1小鼠中,单碳酸盐运输体4 (MCT4) 表达的升高表明了被破坏的天体细胞-神经元乳酸穿 (ANLS) 稳态.

结论:

在AD小鼠模型中,酸化先于Aβ沉积,在沉积开始时达到峰值.
早期酸化可能是由ANLS的破坏驱动的,影响大脑平衡.
这些发现突出了酸性化作为阿尔茨海默病发病的早期事件.

关键词:

阿尔茨海默氏症的疾病是阿尔茨海默氏症.具有酸性反应的酸性反应细胞外酸性化细胞外酸性化单碳酸盐输送器 4 单碳酸盐输送器接近红外的光探测器

更多相关视频

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...